Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biologicals.2019.06.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disappointing long-term efficacy of secukinumab in patients with hidradenitis suppurativa: the need for defining long-term outcomes and evaluating treatment combinations.
Br J Dermatol
January 2025
Service de dermatologie, Hôpital Saint Louis, AP-HP, Université Paris Cité, Paris, France.
Fractional Carbon Dioxide Laser Combined with Secukinumab in the Treatment of Refractory Psoriasis Lesions on the Lower Legs.
Clin Cosmet Investig Dermatol
December 2024
Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, People's Republic of China.
Psoriasis is a chronic autoimmune skin disorder characterized by high morbidity and a tendency for recurrence. Although biologic therapy for lesion clearance can achieve PASI 90/100, refractory sites remain challenging to completely clear, particularly on the lower legs and elbows. To explore the efficacy of novel treatments for these resistant sites, we present a clinical observation on the safety and effectiveness of fractional carbon dioxide (CO2) laser therapy combined with secukinumab for four patients with moderate-to-severe plaque psoriasis.
View Article and Find Full Text PDFEuropean S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.
J Eur Acad Dermatol Venereol
December 2024
European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Introduction: This second part of the S2k guidelines is an update of the 2015 S1 European guidelines.
Objective: These guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).
Methods: The chapters have been selected after a Delphi procedure among the experts/authors.
Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers.
J Pers Med
November 2024
Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, 50134 Florence, Italy.
Article Synopsis
- The study evaluated the effectiveness and retention rate of secukinumab (SCK) in patients with axial spondyloarthritis (ax-SpA) using data from five Italian centers.
- A total of 71 patients were analyzed, showing significant improvements in disease activity over 24 months, with BASDAI scores decreasing from 6.2 to 3.5 and ASDAS-CRP from 2.9 to 1.7.
- Though 72% of patients remained on SCK after two years, those with fibromyalgia had a higher dropout rate, indicating that coexisting conditions may affect treatment adherence.
Impact of treatments on fatigue in axial spondyloarthritis: a systematic review and meta-analysis.
Rheumatology (Oxford)
October 2024
Service de Rhumatologie, CHU Besançon, Besançon, France.
Article Synopsis
- Fatigue is a common and challenging symptom for patients with axial spondyloarthritis (axSpA), and this systematic review aimed to evaluate how different treatments affect fatigue levels.
- The review analyzed 34 studies out of 1672 identified, finding that anti-TNF and anti-IL17 medications significantly reduced fatigue, while non-pharmacological treatments like physical activity also contributed positively.
- Overall, combining DMARDs with non-pharmacological approaches seemed to enhance the reduction in fatigue for axSpA patients, with some differences noted based on gender and type of axSpA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!